Cerenome Reports Interim ReSPECT-LM Data Supporting Repeat Dosing of REYOBIQ™ in Leptomeningeal Metastases at the 2026 SNO Annual Meeting
Key Highlights
- ➤REYOBIQ repeat dosing showed no dose-limiting toxicities or discontinuation-causing adverse events
- ➤207 Gy cumulative LM absorbed dose achieved after three 26.4 mCi administrations
- ➤LM progression occurred in 0/5 evaluable patients at three and six months
- ➤One of four evaluable patients had LM progression by nine months
- ➤Cerenome targets a Phase 2 randomized study in 2027, subject to progress and regulatory alignment
Expert Statements
Eric J. Daniels, Chief Operating Officer of Cerenome
“These interim findings support the feasibility and early tolerability of fractionated REYOBIQ dosing as a way to deliver a higher cumulative radiation dose to the LM compartment”
Eric J. Daniels, Chief Operating Officer of Cerenome
“The LM progression findings among evaluable patients are encouraging, alongside the absence of dose-limiting toxicities to date and consistent radiation delivery across repeat administrations.”
Eric J. Daniels, Chief Operating Officer of Cerenome
“Our focus now is on continued dose escalation and enrollment to define recommended multiple-dose regimens in support of a future randomized study.”
Andrew J. Brenner, M.D., Ph.D., Professor of Medicine at Mays Cancer Center at UT Health San Antonio and lead author of the poster
“The lack of documented LM progression among evaluable patients at the three- and six-month landmarks is early and encouraging, particularly in a population in which most patients had received prior LM therapy”
Andrew J. Brenner, M.D., Ph.D., Professor of Medicine at Mays Cancer Center at UT Health San Antonio and lead author of the poster
“The ability to deliver substantial cumulative radiation doses with consistent repeat-dose delivery and low estimated marrow exposure supports further evaluation.”
Andrew J. Brenner, M.D., Ph.D., Professor of Medicine at Mays Cancer Center at UT Health San Antonio and lead author of the poster
“These findings remain preliminary, and continued enrollment and follow-up are needed to determine the clinical activity of this regimen.”
HOUSTON, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted radiopharmaceuticals, and artificial intelligence, today announced interim data from its ongoing ReSPECT-LM study of repeated intraventricular dosing of REYOBIQ™ (rhenium Re186 obisbemeda) in patients with leptomeningeal metastases (LM). The data were presented as a poster on November 13, 2026, during the Society for Neuro-Oncology (SNO) 31st Annual Meeting and Education Day.
The poster reports treatment exposure, safety, dosimetry, LM progression status, and cerebrospinal fluid (CSF) tumor-cell findings for the first 10 patients treated. No dose-limiting toxicities or adverse events leading to treatment discontinuation have been reported. To date, one patient has received three 26.4 mCi doses, for a total administered activity of 79.2 mCi. This exceeds the highest activity given as a single administration in the prior single-dose ReSPECT-LM study (75 mCi). Furthermore, imaging showed the radiation dose delivered to the LM compartment was consistent from one treatment to the next within each patient, varying by a median of 8%. These levels are consistent with previously reported Phase 1 single-dose data. Dose escalation is ongoing.
Get started
Create a free account to read the full story.
